杏林製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2019/10/11 | 1,767 | 1,780 | 1,759 | 1,773 | +19 | +1.1% | 103,500 |
2019/10/10 | 1,753 | 1,766 | 1,736 | 1,754 | -8 | -0.5% | 140,500 |
2019/10/09 | 1,748 | 1,770 | 1,742 | 1,762 | -4 | -0.2% | 138,600 |
2019/10/08 | 1,745 | 1,771 | 1,742 | 1,766 | +37 | +2.1% | 176,100 |
2019/10/07 | 1,740 | 1,740 | 1,719 | 1,729 | -8 | -0.5% | 100,200 |
2019/10/04 | 1,740 | 1,743 | 1,710 | 1,737 | -14 | -0.8% | 186,800 |
2019/10/03 | 1,790 | 1,790 | 1,741 | 1,751 | -78 | -4.3% | 272,800 |
2019/10/02 | 1,820 | 1,846 | 1,820 | 1,829 | +8 | +0.4% | 162,400 |
2019/10/01 | 1,789 | 1,828 | 1,789 | 1,821 | +32 | +1.8% | 203,400 |
2019/09/30 | 1,791 | 1,798 | 1,772 | 1,789 | -35 | -1.9% | 213,900 |
2019/09/27 | 1,829 | 1,837 | 1,795 | 1,824 | -43 | -2.3% | 199,400 |
2019/09/26 | 1,909 | 1,912 | 1,859 | 1,867 | -34 | -1.8% | 286,200 |
2019/09/25 | 1,866 | 1,907 | 1,858 | 1,901 | +38 | +2% | 273,200 |
2019/09/24 | 1,863 | 1,883 | 1,846 | 1,863 | +14 | +0.8% | 259,000 |
2019/09/20 | 1,841 | 1,866 | 1,832 | 1,849 | +8 | +0.4% | 688,200 |
2019/09/19 | 1,839 | 1,858 | 1,832 | 1,841 | +19 | +1% | 206,100 |
2019/09/18 | 1,834 | 1,838 | 1,815 | 1,822 | -12 | -0.7% | 187,800 |
2019/09/17 | 1,827 | 1,840 | 1,814 | 1,834 | ±0 | ±0% | 192,900 |
2019/09/13 | 1,816 | 1,841 | 1,799 | 1,834 | +32 | +1.8% | 276,200 |
2019/09/12 | 1,816 | 1,817 | 1,796 | 1,802 | -2 | -0.1% | 272,100 |
2019/09/11 | 1,769 | 1,817 | 1,762 | 1,804 | +50 | +2.9% | 362,700 |
2019/09/10 | 1,761 | 1,768 | 1,750 | 1,754 | -5 | -0.3% | 194,500 |
2019/09/09 | 1,752 | 1,759 | 1,742 | 1,759 | +15 | +0.9% | 127,400 |
2019/09/06 | 1,756 | 1,762 | 1,744 | 1,744 | -11 | -0.6% | 188,500 |
2019/09/05 | 1,759 | 1,772 | 1,749 | 1,755 | +5 | +0.3% | 198,800 |
2019/09/04 | 1,748 | 1,750 | 1,722 | 1,750 | -17 | -1% | 158,200 |
2019/09/03 | 1,742 | 1,774 | 1,734 | 1,767 | +16 | +0.9% | 122,900 |
2019/09/02 | 1,774 | 1,774 | 1,746 | 1,751 | -23 | -1.3% | 124,800 |
2019/08/30 | 1,742 | 1,779 | 1,737 | 1,774 | +48 | +2.8% | 243,700 |
2019/08/29 | 1,732 | 1,734 | 1,708 | 1,726 | +3 | +0.2% | 157,700 |
2019/08/28 | 1,748 | 1,748 | 1,717 | 1,723 | -32 | -1.8% | 152,200 |
2019/08/27 | 1,755 | 1,772 | 1,750 | 1,755 | +18 | +1% | 132,900 |
2019/08/26 | 1,740 | 1,752 | 1,731 | 1,737 | -48 | -2.7% | 203,500 |
2019/08/23 | 1,786 | 1,789 | 1,778 | 1,785 | +9 | +0.5% | 138,700 |
2019/08/22 | 1,786 | 1,786 | 1,757 | 1,776 | -1 | -0.1% | 130,800 |
2019/08/21 | 1,782 | 1,789 | 1,777 | 1,777 | -6 | -0.3% | 153,100 |
2019/08/20 | 1,774 | 1,783 | 1,765 | 1,783 | +12 | +0.7% | 123,200 |
2019/08/19 | 1,778 | 1,779 | 1,767 | 1,771 | +10 | +0.6% | 103,500 |
2019/08/16 | 1,735 | 1,777 | 1,730 | 1,761 | +17 | +1% | 128,100 |
2019/08/15 | 1,726 | 1,748 | 1,724 | 1,744 | -25 | -1.4% | 133,000 |
2019/08/14 | 1,751 | 1,774 | 1,751 | 1,769 | +32 | +1.8% | 124,100 |
2019/08/13 | 1,734 | 1,740 | 1,716 | 1,737 | -17 | -1% | 156,600 |
2019/08/09 | 1,751 | 1,768 | 1,749 | 1,754 | +17 | +1% | 126,100 |
2019/08/08 | 1,722 | 1,746 | 1,702 | 1,737 | +15 | +0.9% | 195,300 |
2019/08/07 | 1,724 | 1,732 | 1,711 | 1,722 | -11 | -0.6% | 147,900 |
2019/08/06 | 1,703 | 1,737 | 1,688 | 1,733 | -20 | -1.1% | 229,700 |
2019/08/05 | 1,782 | 1,782 | 1,731 | 1,753 | -48 | -2.7% | 201,500 |
2019/08/02 | 1,800 | 1,819 | 1,786 | 1,801 | -13 | -0.7% | 369,700 |
2019/08/01 | 1,831 | 1,836 | 1,804 | 1,814 | -23 | -1.3% | 214,200 |
2019/07/31 | 1,800 | 1,862 | 1,789 | 1,837 | +26 | +1.4% | 595,700 |
1251~
1300
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
杏林製薬 | 149,900円 | +3.2% | +4.5% | 3.47% | 17.22倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
ゼリア新薬 | 224,400円 | +13.6% | +29.2% | 2.05% | 11.64倍 | 1.12倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
ネクセラファーマ | 113,200円 | +197.7% | - | 0.00% | 46.26倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
JCRファーマ | 72,400円 | -3.7% | -36.7% | 2.76% | 23.84倍 | 1.56倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
栄研化 | 209,200円 | +0.4% | -8.4% | 2.53% | 27.65倍 | 1.57倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム